HRP20161114T1 - Sastavi inhibitora kinaze i njihova uporaba za liječenje raka i drugih bolesti povezanih s kinazama - Google Patents
Sastavi inhibitora kinaze i njihova uporaba za liječenje raka i drugih bolesti povezanih s kinazama Download PDFInfo
- Publication number
- HRP20161114T1 HRP20161114T1 HRP20161114TT HRP20161114T HRP20161114T1 HR P20161114 T1 HRP20161114 T1 HR P20161114T1 HR P20161114T T HRP20161114T T HR P20161114TT HR P20161114 T HRP20161114 T HR P20161114T HR P20161114 T1 HRP20161114 T1 HR P20161114T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- pharmaceutical composition
- group
- substance
- cancer
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 3
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 201000011510 cancer Diseases 0.000 title claims 2
- 108091000080 Phosphotransferase Proteins 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 102000020233 phosphotransferase Human genes 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 239000000126 substance Substances 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 3
- 239000012453 solvate Substances 0.000 claims 3
- 229940124597 therapeutic agent Drugs 0.000 claims 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 claims 1
- 229930003427 Vitamin E Natural products 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229960004679 doxorubicin Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 claims 1
- 229960002411 imatinib Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 claims 1
- 229960003787 sorafenib Drugs 0.000 claims 1
- 239000000725 suspension Substances 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Claims (8)
1. Tvar odabrana iz grupe koja se sastoji od:
[image]
i enantiomera, dijastereoizomera, tautomera, ili njenih farmaceutski prihvatljivih soli ili solvata.
2. Tvar u skladu s patentnim zahtjevom 1, pri čemu je tvar
[image]
ili enantiomer, dijastereoizomer, tautomer, ili njena farmaceutski prihvatljiva sol ili solvat.
3. Tvar odabrana iz grupe koja se sastoji od:
[image]
i enantiomer, dijastereoizomer, tautomer, ili njena farmaceutski prihvatljiva sol ili solvat.
4. Farmaceutski sastav obuhvaća tvar u skladu s patentnim zahtjevima 1, 2 ili 3 i farmaceutski prihvatljiv ekscipijens, nosač, ili diluent.
5. Farmaceutski sastav iz patentnog zahtjeva 4, pri čemu je farmaceutski prihvatljiv ekscipijens, nosač, ili diluent smjesa u otopini ili smjesa u suspenziji koja obuhvaća, prema masi, oko 12.5% dimetilacetamida, oko 52.5% PEG400 i oko 35% od 20%-tnog vitamina E.
6. Farmaceutski sastav iz patentnog zahtjeva 4, nadalje obuhvaća najmanje jedan različiti terapijski agens protiv raka.
7. Farmaceutski sastav iz patentnog zahtjeva 6, pri čemu je navedeni terapijski agens protiv raka najmanje jedan agens odabran iz grupe koja se sastoji od agenasa za radioterapiju (XRT), citotoksičnih agenasa, ciljanih agenasa i adjunktivnih agenasa.
8. Farmaceutski sastav iz patentnog zahtjeva 6 ili 7, pri čemu je navedeni terapijski agens protiv raka odabran iz grupe koja se sastoji gemcitabina, erlotiniba, paklitaksela, docetaksel karboplatine, cisplatine, 5-fluorouracila, doksorubicina, sorafeniba, imatiniba, bevacizumaba, cetuksimaba i trastuzamaba.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97041007P | 2007-09-06 | 2007-09-06 | |
| US1338907P | 2007-12-13 | 2007-12-13 | |
| US7429508P | 2008-06-20 | 2008-06-20 | |
| PCT/US2008/075418 WO2009033033A2 (en) | 2007-09-06 | 2008-09-05 | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases |
| EP08829600.9A EP2197878B1 (en) | 2007-09-06 | 2008-09-05 | Compositions of kinase inhibitors and their use for treatment of cancer and other diseases related to kinases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20161114T1 true HRP20161114T1 (hr) | 2016-11-04 |
Family
ID=40429714
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20161114TT HRP20161114T1 (hr) | 2007-09-06 | 2016-08-31 | Sastavi inhibitora kinaze i njihova uporaba za liječenje raka i drugih bolesti povezanih s kinazama |
Country Status (16)
| Country | Link |
|---|---|
| US (5) | US8299106B2 (hr) |
| EP (2) | EP3037419B1 (hr) |
| JP (5) | JP5452490B2 (hr) |
| CN (1) | CN101848908B (hr) |
| CA (1) | CA2736177A1 (hr) |
| CY (1) | CY1118012T1 (hr) |
| DK (1) | DK2197878T3 (hr) |
| ES (2) | ES2591028T3 (hr) |
| HK (2) | HK1148529A1 (hr) |
| HR (1) | HRP20161114T1 (hr) |
| HU (1) | HUE030774T2 (hr) |
| LT (1) | LT2197878T (hr) |
| PL (1) | PL2197878T3 (hr) |
| PT (1) | PT2197878T (hr) |
| SI (1) | SI2197878T1 (hr) |
| WO (1) | WO2009033033A2 (hr) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101848908B (zh) * | 2007-09-06 | 2014-07-02 | 北京强新生物科技有限公司 | 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途 |
| JP5754942B2 (ja) * | 2007-12-10 | 2015-07-29 | インターデイジタル パテント ホールディングス インコーポレイテッド | 無線リンク制御パケットの破棄および無線リンク制御の再確立をトリガする方法および装置 |
| AU2012222812A1 (en) | 2011-02-28 | 2013-05-02 | Mcmaster University | Treatment of cancer with dopamine receptor antagonists |
| WO2014030001A1 (en) * | 2012-08-23 | 2014-02-27 | The Institute Of Cancer Research: Royal Cancer Hospital | Fused heterocyclic compounds and their use |
| US9227962B2 (en) | 2013-03-13 | 2016-01-05 | Boston Biomedical, Inc. | Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative |
| SG11201507346PA (en) * | 2013-03-13 | 2015-10-29 | Boston Biomedical Inc | 3-(aryl or heteroaryl) methyleneindolin-2-one derivatives as inhibitors of cancer stem cell pathway kinases for the treatment of cancer |
| US9187454B2 (en) | 2013-03-13 | 2015-11-17 | Boston Biomedical, Inc. | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof |
| US20160368870A1 (en) * | 2013-06-20 | 2016-12-22 | Boehringer Ingelheim International Gmbh | Olefin substituted oxindoles having ampk activity |
| CA2936839A1 (en) * | 2014-01-27 | 2015-07-30 | Boston Biomedical, Inc. | Novel methods for treating cancer |
| US10118890B2 (en) | 2014-10-10 | 2018-11-06 | The Research Foundation For The State University Of New York | Trifluoromethoxylation of arenes via intramolecular trifluoromethoxy group migration |
| AU2016255034A1 (en) * | 2015-04-27 | 2017-11-02 | Boston Biomedical, Inc. | Methods for treating cancer with a STAT3 pathway inhibitor and kinase inhibitor |
| JPWO2017026119A1 (ja) * | 2015-08-10 | 2018-05-24 | 大日本住友製薬株式会社 | ５−（チアゾール−４−イル）インドリン−２−オン誘導体の精製方法 |
| WO2017160978A1 (en) | 2016-03-15 | 2017-09-21 | Boston Biomedical, Inc. | Cell cultures and use thereof |
| CA3029596A1 (en) | 2016-06-28 | 2018-01-04 | Boston Biomedical, Inc. | Methods for treating cancer |
| WO2018098352A2 (en) | 2016-11-22 | 2018-05-31 | Jun Oishi | Targeting kras induced immune checkpoint expression |
| CA3045306A1 (en) | 2016-11-29 | 2018-06-07 | Boston Biomedical, Inc. | Naphthofuran derivatives, preparation, and methods of use thereof |
| US20220040172A1 (en) * | 2018-09-18 | 2022-02-10 | 1Globe Biomedical Co., Ltd. | Treatment for non-alcoholic fatty liver disease |
| CN117224541A (zh) * | 2018-09-18 | 2023-12-15 | 北京强新生物科技有限公司 | 肥胖症的治疗 |
| WO2023081923A1 (en) | 2021-11-08 | 2023-05-11 | Frequency Therapeutics, Inc. | Platelet-derived growth factor receptor (pdgfr) alpha inhibitors and uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2547947C (en) * | 1990-11-30 | 2007-09-25 | Masatoshi Chihiro | Azole derivatives as active superoxide radical inhibitors |
| CA2264220A1 (en) * | 1996-08-23 | 1998-02-26 | Sugen, Inc. | Indolinone combinatorial libraries and related products and methods for the treatment of disease |
| GB9716557D0 (en) * | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
| JP2001517666A (ja) * | 1997-09-23 | 2001-10-09 | 藤沢薬品工業株式会社 | チアゾール誘導体 |
| NZ520640A (en) * | 2000-02-15 | 2005-04-29 | Upjohn Co | Pyrrole substituted 2-indolinone protein kinase inhibitors |
| ES2243461T3 (es) * | 2000-02-28 | 2005-12-01 | Sugen, Inc. | Compuestos de 3-(pirolillactona) -2-indolinona como inhibidores quinasa. |
| CA2410509A1 (en) * | 2000-06-02 | 2001-12-13 | Sugen, Inc. | Indolinone derivatives as protein kinase/phosphatase inhibitors |
| ES2360205T3 (es) | 2001-03-02 | 2011-06-01 | Agennix Ag | Sistema de ensayo de tres híbridos. |
| US6797725B2 (en) * | 2001-04-09 | 2004-09-28 | Sugen, Inc. | Prodrugs of a 3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives |
| US20030119839A1 (en) * | 2001-12-13 | 2003-06-26 | Nan-Horng Lin | Protein kinase inhibitors |
| SE0200979D0 (sv) * | 2002-03-28 | 2002-03-28 | Astrazeneca Ab | New compounds |
| US20050032871A1 (en) * | 2002-09-03 | 2005-02-10 | Sugen, Inc. | Sulfonylated pyrrole-2-indolinone derivatives as kinase inhibitors |
| WO2005040116A2 (en) * | 2003-10-24 | 2005-05-06 | Schering Aktiengesellschaft | Indolinone derivatives and their use in treating disease-states such as cancer |
| KR101452520B1 (ko) * | 2006-01-27 | 2014-10-21 | 샹하이 헨그루이 파마수티컬 컴퍼니 리미티드 | 피롤로[3,2-ｃ]피리딘-4-온 2-인돌린온 단백질 키나제 억제제 |
| WO2008145596A1 (en) * | 2007-06-01 | 2008-12-04 | F. Hoffmann-La Roche Ag | Piperidine-amide derivatives |
| CN101848908B (zh) * | 2007-09-06 | 2014-07-02 | 北京强新生物科技有限公司 | 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途 |
| US9187454B2 (en) * | 2013-03-13 | 2015-11-17 | Boston Biomedical, Inc. | Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof |
-
2008
- 2008-09-05 CN CN200880114705.9A patent/CN101848908B/zh active Active
- 2008-09-05 JP JP2010524187A patent/JP5452490B2/ja not_active Expired - Fee Related
- 2008-09-05 DK DK08829600.9T patent/DK2197878T3/en active
- 2008-09-05 HU HUE08829600A patent/HUE030774T2/hu unknown
- 2008-09-05 EP EP16156340.8A patent/EP3037419B1/en active Active
- 2008-09-05 US US12/676,869 patent/US8299106B2/en not_active Expired - Fee Related
- 2008-09-05 WO PCT/US2008/075418 patent/WO2009033033A2/en active Application Filing
- 2008-09-05 PL PL08829600T patent/PL2197878T3/pl unknown
- 2008-09-05 ES ES08829600.9T patent/ES2591028T3/es active Active
- 2008-09-05 CA CA2736177A patent/CA2736177A1/en not_active Abandoned
- 2008-09-05 LT LTEP08829600.9T patent/LT2197878T/lt unknown
- 2008-09-05 PT PT88296009T patent/PT2197878T/pt unknown
- 2008-09-05 ES ES16156340T patent/ES2759347T3/es active Active
- 2008-09-05 EP EP08829600.9A patent/EP2197878B1/en active Active
- 2008-09-05 SI SI200831667A patent/SI2197878T1/sl unknown
-
2011
- 2011-03-21 HK HK11102786.1A patent/HK1148529A1/xx unknown
-
2012
- 2012-08-27 US US13/595,708 patent/US20120321622A1/en not_active Abandoned
-
2013
- 2013-12-27 JP JP2013272195A patent/JP5701372B2/ja not_active Expired - Fee Related
-
2014
- 2014-07-29 US US14/445,783 patent/US9725444B2/en not_active Expired - Fee Related
-
2015
- 2015-02-17 JP JP2015028165A patent/JP5974124B2/ja not_active Expired - Fee Related
-
2016
- 2016-07-15 JP JP2016140101A patent/JP6495868B2/ja not_active Expired - Fee Related
- 2016-08-31 HR HRP20161114TT patent/HRP20161114T1/hr unknown
- 2016-09-13 CY CY20161100904T patent/CY1118012T1/el unknown
- 2016-12-20 HK HK16114487A patent/HK1226071A1/zh unknown
-
2017
- 2017-07-07 US US15/643,608 patent/US20180022743A1/en not_active Abandoned
-
2018
- 2018-11-14 US US16/190,669 patent/US20190248781A1/en not_active Abandoned
-
2019
- 2019-02-08 JP JP2019021397A patent/JP2019070051A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20161114T1 (hr) | Sastavi inhibitora kinaze i njihova uporaba za liječenje raka i drugih bolesti povezanih s kinazama | |
| KR101098061B1 (ko) | 신생혈관형성 및/또는 증가된 혈관 투과성과 관련된 질병의치료에서 젬시타빈 및 임의로 이온화 방사선과 병용되는퀴나졸린 유도체 ｚｄ6474의 용도 | |
| MX2019010354A (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, metodo de preparacion del mismo y usos medicos del mismo. | |
| HRP20150825T1 (hr) | Imidazo[1,2,-a]piridinski derivati kao inhibitori fgfr kinaze za uporabu u terapiji | |
| KR101667641B1 (ko) | 데시타빈 및 프로카인과 같은 ｄｎａ 메틸전이효소 저해제와 사팍시타빈 또는 ｃｎｄａｃ의 조합 | |
| JP2017517548A5 (hr) | ||
| BR112018004175B8 (pt) | Composto pirazolo[3,4-d]pirimidina, composição farmacêutica e usos terapêuticos do dito composto | |
| HRP20140953T1 (hr) | Morfolino pirimidini i njihova uporaba za lijeäśenje | |
| TW200602328A (en) | Quinazoline derivatives | |
| JP2010522194A5 (hr) | ||
| MX2010003927A (es) | Derivados de pirrolo [2,3-d] pirimidina como inhibidores de proteinas cinasas b. | |
| BRPI0513050A (pt) | derivado de perimidina ou um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, processo para a preparação do mesmo, composição farmacêutica, uso de um derivado de pirimidina ou de um sal, solvato ou pró-droga farmaceuticamente aceitável do mesmo, e, método para produzir um efeito anti-proliferativo em um animal de sangue quente | |
| AR062526A1 (es) | DERIVADOS DE 4-(3-METILMORFOLIN-4-IL)PIRIMIDINA Y MORFOLIN-4-IL-PIRIMIDINA COMO INHIBIDORES DE MTOR QUINASA Y PI3K, UNA COMPOSICIoN FARMACEUTICA QUE LOS COMPRENDE Y EL USO DE LOS MISMOS EN LA FABRICACION DE MEDICAMENTOS PARA EL TRATAMIENTO DE DIVERSOS TIPOS DE CANCER. | |
| RU2017104909A (ru) | Лечение рака комбинацией лучевой терапии, наночастиц оксида церия и химиотерапевтического средства | |
| KR20170124641A (ko) | 항종양 알칼로이드를 이용한 병용요법 | |
| ECSP099382A (es) | Sulfonamidas heterocíclicos que tienen actividad antagonista edg-i | |
| KR101767859B1 (ko) | 아자 2 고리형 화합물을 사용한 암 병용 요법 | |
| ATE502675T1 (de) | Verbindungen, die den ampa-rezeptor verstärken, und deren anwendung in der medizin | |
| JP2012524103A5 (hr) | ||
| HRP20150530T1 (hr) | Spojevi korisni za inhibiranje chk1 | |
| AU2011279836A1 (en) | Combination therapy using a ruthenium complex | |
| JP2021512110A (ja) | ペンタアザ大環状環複合体および白金を基にした抗癌剤による組み合わせ癌療法 | |
| UY30847A1 (es) | Uso de derivados de mononitrato de dianhidrohexita como agentes para el tratamiento de trastornos intestinales | |
| CA2837042A1 (en) | A synergistic pharmaceutical combination for the treatment of squamous cell carcinoma of head and neck | |
| AU775305B2 (en) | Combination therapy using pentafluorobenzenesulfonamide and platin compound |